Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Eucomed targets trade barriers in new EU members:

This article was originally published in Clinica

Executive Summary

Market access hurdles in Poland and the Czech Republic were among the priorities issues identified by Eucomed's Enlargement Focus Group (ENL) at a meeting on November 18. ENL is concerned in particular about mandatory notification in Poland involving notarised documents and authorised translations. Another issue is the Czech requirement for notarised copies and notification requested for reimbursement purposes. The ENL has also identified as a priority encouraging the realisation of trade agreements between the EU and the second wave entry countries, Bulgaria, Romania and Croatia in medical devices prior to their accession, planned for 2007. These trade agreements are know as PECAs (Protocols to the Europe Agreement on Conformity Assessment and Acceptance of Industrial Products).

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT060310

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel